Urology
Volume 75, Issue 2 , Pages 399-405 , February 2010

The Unintended Burden of Increased Prostate Cancer Detection Associated With Prostate Cancer Screening and Diagnosis

  • Peter C. Albertsen

      Affiliations

    • Corresponding Author InformationReprint requests: Peter C. Albertsen, M.D., Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030-3955

Received 10 March 2009 ,Accepted 6 August 2009.

References 

  1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007;
  2. Issa MM, Fenter TC, Black L, et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12:S83–S89
  3. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–278
  4. American Urological Association. Prostate-specific antigen best practice statement: 2009 update. 2009;
  5. ACS, American Cancer Society. Guidelines for the Early Detection of Cancer. http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp2008;Accessed July 2, 2008
  6. USPSTF. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–191
  7. Albertsen PC. PSA testing: public policy or private penchant?. J Am Med Assoc. 2006;296:2371–2373
  8. Bloch S, Love A, Macvean M, et al. Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med. 2007;1:2
  9. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  10. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  11. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9:445–452
  12. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–S19
  13. Andriole GL, Levin DL, Crawford ED, et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005;97:433–438
  14. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  15. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101:894–904
  16. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer (Prostate Patient Outcomes Research Team). J Am Med Assoc. 1993;269:2650–2658
  17. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299–305
  18. Dale W, Bilir P, Han M, et al. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104:467–478
  19. Korfage IJ, de Koning HJ, Roobol M, et al. Prostate cancer diagnosis: the impact on patients' mental health. Eur J Cancer. 2006;42:165–170
  20. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112:1650–1659
  21. Martin RM, Gunnell D, Hamdy F, et al. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol. 2006;176:439–449
  22. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520–1524
  23. Bacon CG, Giovannucci E, Testa M, et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94:862–871
  24. Turini M, Redaelli A, Gramegna P, et al. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics. 2003;21:527–541
  25. Penson DF. Quality of life after therapy for localized prostate cancer. Cancer J. 2007;13:318–326
  26. Stone P, Richards M, A'Hern R, et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000;11:561–567
  27. Truong PT, Berthelet E, Lee JC, et al. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. Can J Urol. 2006;13:3139–3146
  28. Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology. 1997;49:207–216Discussion: 216-207
  29. Litwin MS, Lubeck DP, Stoddard ML, et al. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol. 2001;165:871–875
  30. Stewart ST, Lenert L, Bhatnagar V, et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347–355
  31. Clark JA, Inui TS, Silliman RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol. 2003;21:3777–3784
  32. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239–2247
  33. Hoffman RM, Gilliland FD, Penson DF, et al. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer. 2004;101:2011–2019
  34. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst. 2000;92:1582–1592
  35. Mantz CA, Nautiyal J, Awan A, et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999;5:230–236
  36. Bradley EB, Bissonette EA, Theodorescu D. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. BJU Int. 2004;94:1003–1009
  37. Buron C, Le Vu B, Cosset JM, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys. 2007;67:812–822
  38. Weber BA, Roberts BL, Chumbler NR, et al. Urinary, sexual, and bowel dysfunction and bother after radical prostatectomy. Urol Nurs. 2007;27:527–533
  39. Helgason AR, Adolfsson J, Dickman P, et al. Waning sexual function—the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 1996;73:1417–1421
  40. Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int. 2007;99(Suppl 1):25–29Discussion: 30
  41. Trask PC. Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy. Health Qual Life Outcomes. 2004;2:37
  42. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another? (a review of patient decision making for localized prostate cancer). Cancer. 2006;106:1865–1874
  43. Northouse LL, Mood DW, Montie JE, et al. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol. 2007;25:4171–4177
  44. Fleshner N, Gomella LG, Cookson MS, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the reduction by dutasteride of clinical progression events in expectant management (REDEEM) trial. Contemp Clin Trials. 2007;28:763–769
  45. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007;178:S9–S13
  46. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E Cancer Prevention Trial (SELECT). J Am Med Assoc. 2009;301:39–51
  47. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the physicians' health study II randomized controlled trial. J Am Med Assoc. 2009;301:52–62
  48. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res. 2008;1:174–181
  49. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314–1317

 Responsibility for opinions, conclusions, and interpretation of data lies with the author.

PII: S0090-4295(09)02610-7

doi: 10.1016/j.urology.2009.08.078

Urology
Volume 75, Issue 2 , Pages 399-405 , February 2010

Article Tools

* Image Usage & Resolution